posted on 2016-10-21, 00:00authored byNarges Abdali, Jerry
M. Parks, Keith M. Haynes, Julie L. Chaney, Adam T. Green, David Wolloscheck, John K. Walker, Valentin V. Rybenkov, Jerome Baudry, Jeremy
C. Smith, Helen I. Zgurskaya
Antibiotic resistance is a major
threat to human welfare. Inhibitors of multidrug efflux pumps (EPIs)
are promising alternative therapeutics that could revive activities
of antibiotics and reduce bacterial virulence. Identification of new
druggable sites for inhibition is critical for the development of
effective EPIs, especially in light of constantly emerging resistance.
Here, we describe EPIs that interact with periplasmic membrane fusion
proteins, critical components of efflux pumps that are responsible
for the activation of the transporter and the recruitment of the outer-membrane
channel. The discovered EPIs bind to AcrA, a component of the prototypical
AcrAB-TolC pump, change its structure in vivo, inhibit efflux of fluorescent
probes, and potentiate the activities of antibiotics in Escherichia coli and other Gram-negative bacteria.
Our findings expand the chemical and mechanistic diversity of EPIs,
suggest the mechanism for regulation of the efflux pump assembly and
activity, and provide a promising path for reviving the activities
of antibiotics in resistant bacteria.